Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry

BMC Nephrology

Roser Torra⁴  Elisabet Ars²  José Ballarín³  Juan Cabezuelo¹  Salomé Muray¹  Joan Manel Díaz⁵  Emma Arcos³  Jordi Comas³  Víctor Martínez¹ 

[1] Nephrology Department, Hospital Reina Sofia, Murcia, Spain;Molecular Biology Laboratory, Fundacio Puigvert, IIB Sant Pau, Univeristat Autónoma de Barcelona, Barcelona, Spain;Catalan Renal Registry, Catalan Transplant Organization, Health Department, Generalitat of Catalonia, Barcelona, Spain;Inherited Renal Diseases, Nephrology Department, Fundacio Puigvert, IIB Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain;Nephrology Department, Fundacio Puigvert, IIB Sant Pau, Univeristat Autónoma de Barcelona, Barcelona, Spain

关键词: ADPKD;    Co-morbidities;    Survival;    Renal replacement therapy;    Autosomal dominant polycystic kidney disease;   

Others  :  1082853
DOI  :  10.1186/1471-2369-14-186

 received in 2013-05-14, accepted in 2013-09-04,  发布年份 2013

【 摘 要 】

Background

Some 7-10% of patients on replacement renal therapy (RRT) are receiving it because of autosomal dominant polycystic kidney disease (ADPKD). The age at initiation of RRT is expected to increase over time.

Methods

Clinical data of 1,586 patients (7.9%) with ADPKD and 18,447 (92.1%) patients with other nephropathies were analysed from 1984 through 2009 (1984–1991, 1992–1999 and 2000–2009).

Results

The age at initiation of RRT remained stable over the three periods in the ADPKD group (56.7 ± 10.9 (mean ± SD) vs 57.5 ± 12.1 vs 57.8 ± 13.3 years), whereas it increased significantly in the non-ADPKD group (from 54.8 ± 16.8 to 63.9 ± 16.3 years, p < 0.001). The ratio of males to females was higher for non-ADPKD than for ADPKD patients (1.6–1.8 vs 1.1–1.2). The prevalence of diabetes was significantly lower in the ADPKD group (6.76% vs 11.89%, p < 0.001), as were most of the co-morbidities studied, with the exception of hypertension. The survival rate of the ADPKD patients on RRT was higher than that of the non-ADPKD patients (p < 0.001).

Conclusions

Over time neither changes in age nor alterations in male to female ratio have occurred among ADPKD patients who have started RRT, probably because of the impact of unmodifiable genetic factors in the absence of a specific treatment.

【 授权许可】

   
2013 Martínez et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Harris PC: 2008 Homer W. Smith Award: insights into the pathogenesis of polycystic kidney disease from gene discovery. J Am Soc Nephrol 2009, 20:1188-1198.
• [2]Torra R, Badenas C, Darnell A, Nicolau C, Volpini V, Revert L, et al.: Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. J Am Soc Nephrol 1996, 7:2142-2151.
• [3]Hateboer N, Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, et al.: Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999, 353:103-107.
• [4]Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, et al.: US Renal Data System 2010 Annual Data Report. Am J Kidney Dis 2011, 57:A8, e1-A8,526.
• [5]Catalan Transplant Organisation HD: Generalitat de Catalunya. Barcelona: Generalitat de Catalunya, Servei Catala de la Salut; 2009. [Catalan Renal Registry] Statistical report. 20-11-2011. Ref Type: Catalog
• [6]Taylor M, Johnson AM, Tison M, Fain P, Schrier RW: Earlier diagnosis of autosomal dominant polycystic kidney disease: importance of family history and implications for cardiovascular and renal complications. Am J Kidney Dis 2005, 46:415-423.
• [7]Audrezet MP, Cornec-Le GE, Chen JM, Redon S, Quere I, Creff J, et al.: Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients. Hum Mutat 2012, 33:1239-1250.
• [8]Cornec-Le GE, Audrezet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al.: Type of PKD1 Mutation Influences Renal Outcome in ADPKD. J Am Soc Nephrol 2013, 24:1006-1013.
• [9]Chapman AB, Stepniakowski K, Rahbari-Oskoui F: Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010, 17:153-163.
• [10]Higashihara E, Horie S, Muto S, Mochizuki T, Nishio S, Nutahara K: Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol 2012, 16:622-628.
• [11]Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al.: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002, 13:1918-1927.
• [12]Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J: Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003, 14:2934-2941.
• [13]Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT: Health care utilization among patients with chronic kidney disease. Kidney Int 2002, 62:229-236.
• [14]Molnar MZ, Lukowsky LR, Streja E, Dukkipati R, Jing J, Nissenson AR, et al.: Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease. J Hypertens 2010, 28:2475-2484.
• [15]Reed BY, McFann K, Reza BM, Nobkhthaghighi N, Masoumi A, Johnson AM, et al.: Variation in age at ESRD in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2008, 51:173-183.
• [16]Orskov B, Romming S, Feldt-Rasmussen B, Strandgaard S, V: Improved Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease in Denmark. Clin J Am Soc Nephrol 2010, 5:2034-2039.
• [17]Schrier RW, McFann KK, Johnson AM: Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int 2003, 63:678-685.
• [18]Patch C, Charlton J, Roderick PJ, Gulliford MC: Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis 2011, 57:856-862.
• [19]Stewart JH: End-stage renal failure appears earlier in men than in women with polycystic kidney disease. Am J Kidney Dis 1994, 24:181-183.
• [20]Jacquet A, Pallet N, Kessler M, Hourmant M, Garrigue V, Rostaing L, et al.: Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int 2011, 24:582-587.
• [21]Jager KJ, van Dijk PC, Dekker FW, Stengel B, Simpson K, Briggs JD: The epidemic of aging in renal replacement therapy: an update on elderly patients and their outcomes. Clin Nephrol 2003, 60:352-360.
• [22]Gretz N, Zeier M, Geberth S, Strauch M, Ritz E: Is gender a determinant for evolution of renal failure? A study in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1989, 14:178-183.
• [23]Wakai K, Nakai S, Kikuchi K, Iseki K, Miwa N, Masakane I, et al.: Trends in incidence of end-stage renal disease in Japan, 1983–2000: age-adjusted and age-specific rates by gender and cause. Nephrol Dial Transplant 2004, 19:2044-2052.
• [24]Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, et al.: Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002, 13:1733-1739.
• [25]Abbott KC, Agodoa LY: Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2002, 57:208-214.
• [26]Li L, Szeto CC, Kwan BC, Chow KM, Leung CB, Kam-Tao LP: Peritoneal dialysis as the first-line renal replacement therapy in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2011, 57:903-907.
• [27]Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, et al.: Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992, 41:1311-1319.
• [28]Dicks E, Ravani P, Langman D, Davidson WS, Pei Y, Parfrey PS: Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years. Clin J Am Soc Nephrol 2006, 1:710-717.
• [29]Yium J, Gabow P, Johnson A, Kimberling W, Martinez-Maldonado M: Autosomal dominant polycystic kidney disease in blacks: clinical course and effects of sickle-cell hemoglobin. J Am Soc Nephrol 1994, 4:1670-1674.
• [30]Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, et al.: Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 2001, 21:98-103.
• [31]Ozkok A, Akpinar TS, Tufan F, Kanitez NA, Uysal M, Guzel M, et al.: Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience. Clin Exp Nephrol 2012, 17:345-351.
• [32]Helal I, Reed B, Schrier RW: Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment. Am J Nephrol 2012, 36:162-167.
• [33]Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF Jr, et al.: Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011, 6:640-647.
• [34]Virzi GM, Corradi V, Panagiotou A, Gastaldon F, Cruz DN, de CM, et al.: ADPKD: Prototype of Cardiorenal Syndrome Type 4. Int J Nephrol 2010, 2011:490795.
• [35]Abbott KC, Agodoa LY: Polycystic kidney disease in patients on the renal transplant waiting list: trends in hematocrit and survival. BMC Nephrol 2002, 3:7. BioMed Central Full Text
• [36]Lukowsky LR, Molnar MZ, Zaritsky JJ, Sim JJ, Mucsi I, Kovesdy CP, et al.: Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant 2012, 27:2899-2907.
• [37]Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M: Inflammation, Oxidative Stress, and Insulin Resistance in Polycystic Kidney Disease. Clin J Am Soc Nephrol 2010, 6:7-13.
• [38]Torra R, Darnell A, Cleries M, Botey A, Revert L, Vela E: Polycystic kidney disease patients on renal replacement therapy: data from the Catalan Renal Registry. Contrib Nephrol 1995, 115:177-181.
• [39]Helal I, Reed B, Mettler P, Mc FK, Tkachenko O, Yan XD, et al.: Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease. Am J Nephrol 2012, 36:362-370.
• [40]Herbelin A, Urena P, Nguyen AT, Zingraff J, scamps-Latscha B: Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991, 39:954-960.
• [41]Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, et al.: Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int 2012, 81:577-585.
• [42]Johnston O, O’Kelly P, Donohue J, Walshe JJ, Little DM, Hickey D, et al.: Favorable graft survival in renal transplant recipients with polycystic kidney disease. Ren Fail 2005, 27:309-314.
• [43]Orskov B, Sorensen VR, Feldt-Rasmussen B, Strandgaard S: Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol Dial Transplant 2012, 27:1607-1613.
• [44]Fick GM, Johnson AM, Hammond WS, Gabow PA: Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995, 5:2048-2056.
• [45]Rahman E, Niaz FA, Al-Suwaida A, Nahrir S, Bashir M, Rahman H, et al.: Analysis of causes of mortality in patients with autosomal dominant polycystic kidney disease: a single center study. Saudi J Kidney Dis Transpl 2009, 20:806-810.
• [46]Haynes R, Kheradmand F, Winearls CG: Survival after starting renal replacement treatment in patients with autosomal dominant polycystic kidney disease: a single-centre 40-year study. Nephron Clin Pract 2012, 120:c42-c47.
• [47]Roscoe JM, Brissenden JE, Williams EA, Chery AL, Silverman M: Autosomal dominant polycystic kidney disease in Toronto. Kidney Int 1993, 44:1101-1108.
• [48]Alam A, Perrone RD: Management of ESRD in patients with autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010, 17:164-172.
• [49]Fourtounas C, Panteris V, Valis D: Survival after end-stage renal disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2002, 39:660.
• [50]Perrone RD, Ruthazer R, Terrin NC: Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis 2001, 38:777-784.
• [51]Lee PW, Chien CC, Yang WC, Wang JJ, Lin CC: Epidemiology and mortality in dialysis patients with and without polycystic kidney disease: a national study in Taiwan. J Nephrol 2012, 12(26):755-762.